| Patient | Elizabeth Barrett Browning |
|---|---|
| Date of birth | 1987-03-06 |
| Identifiers | MRN HR-NI026-SYN; SSN (made up) 000-26-4157 |
| Document date | 2026-10-19 |
| Author | Clementine Haverford-Asante, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Seven-month review after an exacerbation: lungs, opioid therapy, mood, safety, weight, and vaccines. [S]
Ms. Barrett Browning returns seven months after diagnosis and ten weeks after an exacerbation of bronchiectasis, treated at home with amoxicillin for 14 days; the culture from that visit grew Haemophilus influenzae sensitive to amoxicillin, and she was back to her usual sputum within two weeks. She has had no blood since. She finished her sixteen grief sessions in July and had one booster session last month. She has stayed at morphine solution 4 mL twice daily since June, by her choice through the summer and the chest infection, and now asks for the next small step. She is writing every day and has gained weight. [S]
| Element | Detail |
|---|---|
| Exacerbation | One in August, treated at home; recovered in two weeks |
| Opioid | 8 mg twice daily since June; asks for the next step |
| Grief therapy | Sixteen sessions completed and one booster |
| Weight | 44.2 kg |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy good |
| Respiratory | Positive | Morning cough with about a tablespoon of sputum; no blood |
| Gastrointestinal | Negative | Appetite good; stools regular |
| Psychiatric | Negative | Mood steady; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Morphine sulfate 2 mg/mL oral solution, 5 mL (10 mg) by mouth twice daily, morning and bedtime (20 mg a day; long-standing prescription, continued) | 5 mL (10 mg) twice daily, morning and bedtime | Oral route | 2019-03-01 to 2026-04-19 | completed | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeat in 2 to 3 minutes in the other nostril if no response; call 911 | As needed for suspected overdose; keep two devices at home | Nasal route | 2026-03-16 | active | S |
| Cholecalciferol (vitamin D3) 1000 unit (25 mcg) oral tablet, two tablets (2000 units) by mouth daily | Two tablets daily | Oral route | 2026-03-16 | active | S |
| Amoxicillin 500 mg oral capsule, one capsule by mouth three times daily for 14 days | One capsule three times daily for 14 days | Oral route | 2026-08-10 to 2026-08-23 | completed | S |
| Morphine sulfate 2 mg/mL oral solution, 4.5 mL (9 mg) by mouth twice daily, morning and bedtime (18 mg a day) | 4.5 mL (9 mg) twice daily, morning and bedtime | Oral route | 2026-04-20 to 2026-06-14 | completed | S |
| Morphine sulfate 2 mg/mL oral solution, 4 mL (8 mg) by mouth twice daily, morning and bedtime (16 mg a day) | 4 mL (8 mg) twice daily, morning and bedtime | Oral route | 2026-06-15 to 2026-10-18 | completed | S |
| Morphine sulfate 2 mg/mL oral solution, 3.5 mL (7 mg) by mouth twice daily, morning and bedtime (14 mg a day) | 3.5 mL (7 mg) twice daily, morning and bedtime | Oral route | 2026-10-19 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-19 | Body height | 157 | cm | S |
| 2026-10-19 | Body weight | 44.2 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 17.9 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 82 | /min | S |
| 2026-10-19 | Respiratory rate | 16 | /min | S |
| 2026-10-19 | Body temperature | 36.6 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-19 | C reactive protein [Mass/volume] in Serum or Plasma | 3.2 | mg/L | <=5 mg/L | Normal | S |
| 2026-10-19 | Leukocytes [#/volume] in Blood by Automated count | 7.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-19 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S |
Vital signs recorded on 2026-10-19; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 44.2 kg, BMI 17.9 |
| Respiratory | A few crackles at the left base; no wheeze |
| Neurological | Not drowsy; pupils normal size |
| Psychiatric | Warm and engaged; no suicidal ideation |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic cough with daily yellow sputum, occasional streaks of blood, and breathlessness on stairs, worse in winter, for several years after an illness with blood in the sputum about eight years ago; tuberculosis, nontuberculous mycobacteria and bronchiectasis to be distinguished | resolved | confirmed | R05.3 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis at the consultation; it echoes her documented chest illness (D). |
| Non-cystic fibrosis bronchiectasis of the left lower lobe and lingula with chronic Haemophilus influenzae infection and mild airflow obstruction (Bronchiectasis Severity Index 3, mild); tuberculosis and nontuberculous mycobacterial disease excluded; synthetic modern diagnosis chosen for a historical chest illness whose cause is disputed | active | confirmed | J47.9 | S — Synthetic modern diagnosis; the nature of her historical chest illness remains undetermined (R, disputed). |
| Long-term prescribed opioid therapy (oral morphine 20 mg a day for many years, for cough, sleeplessness and palpitations), with expected physiological dependence; no opioid use disorder on DSM-5-TR assessment | active | confirmed | Z79.891 | S — Synthetic modern problem anchored to her documented prescribed opium (D); tolerance and withdrawal on prescribed opioids do not count toward opioid use disorder. |
| Prolonged grief disorder after the drowning of her closest brother five years ago, with yearning, self-blame, avoidance of reminders of the sea, and depressive symptoms (PHQ-9 12); no suicidal ideation | active | confirmed | F43.81 | S — Synthetic modern diagnosis anchored to her documented bereavement (D); not a claim about her real mental health. |
| Vitamin D deficiency (25-hydroxyvitamin D 15 ng/mL) in a woman who rarely goes outdoors | resolved | confirmed | E55.9 | S — Synthetic finding at intake; repleted by twelve weeks. |
| Underweight (BMI 16.8) with a small appetite | active | confirmed | R63.6 | S — Synthetic finding at intake. |
| Exacerbation of bronchiectasis (more sputum, purulent sputum, more cough and breathlessness for three days, with low-grade fever), treated with amoxicillin for 14 days and more frequent airway clearance; resolved | resolved | confirmed | J47.1 | S — Synthetic intercurrent exacerbation; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Sputum bacterial culture | At each review and at every exacerbation, before antibiotics | Completed today | Normal flora only; the August exacerbation sample grew Haemophilus influenzae sensitive to amoxicillin |
| Laboratory | C-reactive protein and white cell count | After an exacerbation | Completed today | CRP 3.2 mg/L; white count 7.4 |
| Self-management | Airway clearance technique and exercise | Every visit | Completed today | Twice daily, four times a day during the exacerbation |
| Self-management | Exacerbations: number in the past year, written plan, and rescue antibiotic | Every visit | Completed today | One in seven months, treated at home; plan renewed |
| Self-management | Hemoptysis: amount, and when to seek emergency care | Every visit | Completed today | None since the exacerbation |
| Self-management | Influenza and pneumococcal vaccines | Influenza yearly; pneumococcal once | Completed today | Influenza vaccine today; PCV20 in July |
| Imaging | Spirometry and Bronchiectasis Severity Index | At diagnosis, then yearly | Due | At one year |
| Laboratory | Mycobacterial culture including nontuberculous mycobacteria | At diagnosis (final at six to eight weeks), then yearly and with unexplained decline | Due | At one year |
| Medication safety | Opioid benefits and harms: function, sleep, cough, sedation, breathing, constipation, and her goals | Every visit, and at least every three months | Completed today | No sedation; sleep and cough better; third step chosen |
| Medication safety | Dose reduction at her request: withdrawal symptoms and sleep | Four weeks after each step | Completed today | Second step tolerated without symptoms |
| Medication safety | Prescription drug monitoring program check | With every prescription, and at least every three months | Completed today | One prescriber, one pharmacy |
| Medication safety | Naloxone at home, and no benzodiazepines or other sedatives | Every visit | Completed today | Naloxone in date; no sedatives |
| Survey | PHQ-9 | At least monthly during active treatment (CMID) | Deferred | Missed: no PHQ-9 was recorded between the June visit and today, although the protocol calls for one at least monthly during active treatment. No harm judging by the PHQ-2 of 1 at the July preventive visit, the stable mood at the August sick visit, and today's PHQ-9 of 5. Corrective action: the psychologist's session scores are now entered in the chart, and a monthly PHQ-9 is sent through the patient portal |
| Examination | Suicide risk review and safety plan | Every visit | Completed today | No suicidal ideation; plan kept |
| Self-management | Grief therapy attendance and response | Weekly for sixteen sessions, then boosters | Completed today | Sixteen sessions completed and one booster |
| Examination | Weight and BMI | Every visit | Completed today | 44.2 kg, BMI 17.9 |
| Self-management | Hepatitis B vaccine | Two doses at least four weeks apart | Completed today | Dose 2 given today; series complete |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Influenza vaccine, inactivated, this season [S]
Guideline basis: British Thoracic Society Guideline for Bronchiectasis in Adults (2019); European Respiratory Society guidelines for the management of adult bronchiectasis (2017); Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (2020); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR): opioid use disorder and prolonged grief disorder criteria (2022); Shear MK, et al. Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial (2016); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression and osteoporosis monographs (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Review in three months with the PHQ-9 and the opioid plan; spirometry, Bronchiectasis Severity Index, sputum and mycobacterial cultures and a urine drug test at one year; pulmonology review if exacerbations reach three a year or blood returns. [S]